{
    "clinical_study": {
        "@rank": "124209", 
        "arm_group": [
            {
                "arm_group_label": "Zolpidem", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder"
            }
        ], 
        "brief_summary": {
            "textblock": "The number of people seeking treatment for marijuana-related problems is on the rise, yet\n      there is no currently accepted medication proven to help them quit. Frequent marijuana users\n      have reported that they have trouble sleeping when they try to quit, and that the loss of\n      sleep can lead to relapse. This research is designed to measure the severity of sleep\n      problems in people as they are trying to quit heavy use of marijuana, and to investigate\n      whether extended-release zolpidem (Ambien CR\u00ae) can improve quit rates among people trying to\n      stop using marijuana."
        }, 
        "brief_title": "The Role of Sleep in the Treatment of Cannabis Use Disorders", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug Addiction", 
        "condition_browse": {
            "mesh_term": [
                "Marijuana Abuse", 
                "Substance-Related Disorders", 
                "Behavior, Addictive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18-55 years.\n\n          2. Recent problematic use of cannabis\n\n          3. Cannabis use impacts sleep\n\n        Exclusion Criteria:\n\n          1. Dependent on drugs other than cannabis or nicotine, or current Axis I psychiatric\n             disorder\n\n          2. Moderate sleep apnea or periodic limb movement disorder\n\n          3. Pregnant, breast feeding, or planning to become pregnant within the next 3 months\n\n          4. Current condition associated with severe cognitive/social impairment\n\n          5. Allergy to any ingredient in extended-release zolpidem or prior adverse reaction to\n             zolpidem\n\n          6. Current use of drugs that affect metabolism via cytochrome P450 or current illness\n             resulting in severe hepatic impairment\n\n          7. Current use of hypnotic medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685073", 
            "org_study_id": "NA_00068969"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zolpidem", 
                "description": "nightly administration of zolpidem extended-release", 
                "intervention_name": "Zolpidem extended-release", 
                "intervention_type": "Drug", 
                "other_name": "Ambien CR"
            }, 
            {
                "arm_group_label": [
                    "Zolpidem", 
                    "Placebo"
                ], 
                "description": "a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants", 
                "intervention_name": "MET/CBT", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Zolpidem"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "marijuana", 
            "cannabis", 
            "treatment", 
            "insomnia", 
            "relapse"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "elenoir1@jhmi.edu", 
                "last_name": "Eva Lenoir", 
                "phone": "410-550-1929"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21224"
                }, 
                "name": "Johns Hopkins University"
            }, 
            "investigator": {
                "last_name": "Ryan Vandrey, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Sleep in the Treatment of Cannabis Use Disorders", 
        "overall_contact": {
            "email": "elenoir1@jhmi.edu", 
            "last_name": "Eva Lenoir", 
            "phone": "410-550-1929"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Ryan Vandrey, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Sleep will be objectively measured at 5 time points during the study assessment period using ambulatory polysomnography (PSG) equipment.", 
                "measure": "Sleep Efficiency", 
                "safety_issue": "No", 
                "time_frame": "up to 24 Weeks"
            }, 
            {
                "description": "Urine drug testing will determine whether study participants are abstinent from cannabis use throughout participation in treatment (12 weeks) and at 3- and 6-month follow-up assessments", 
                "measure": "Cannabis Abstinence", 
                "safety_issue": "No", 
                "time_frame": "Twice weekly on Weeks 1-12; Week 24 and 36"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685073"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Ryan Vandrey", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}